Research across borders

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find studies Explore world registries Peptide directory

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-10-07 21:51 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase not reported / not applicableCompletedOBSERVATIONAL

SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULTICENTER STUDY. SEVERAL STUDY.

ClinicalTrials.gov · NCT05136287 · Registry updated: 2024-02-28

Condition / research focus: Weight Loss; Diabetes Mellitus, Type 2; Quality of Life; Safety Issues
Sponsor: Jose Seijas Amigo
Countries with listed sites: Spain
Registry dates and results: Start: 2022-02-01. Completion: 2024-01-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GLP-1 receptor agonist (drug)

Where the study takes place — 11 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

Centro de Salud de Culleredo
Culleredo, A Coruña, Spain
Site recruitment: Not reported
Centro de Salud de Fene
Fene, A Coruña, Spain
Site recruitment: Not reported
Centro de Salud de Ribeira
Ribeira, A Coruña, Spain
Site recruitment: Not reported
Hospital Clínico Universitario de Santiago de Compostela
Santiago de Compostela, A Coruña, Spain
Site recruitment: Not reported
Centro de Salud de Ribadeo
Ribadeo, Lugo, Spain
Site recruitment: Not reported
Centro de Salud de Vilalba
Vilalba, Lugo, Spain
Site recruitment: Not reported
Centro de Salud de O Carballiño
O Carballiño, Ourense, Spain
Site recruitment: Not reported
Centro de Salud Valmiñor
Nigrán, Pontevedra, Spain
Site recruitment: Not reported
Centro de Salud de O Ventorrillo
A Coruña, Spain
Site recruitment: Not reported
Centro de Salud de San Roque
Lugo, Spain
Site recruitment: Not reported
Centro de Salud Virxe Peregrina
Pontevedra, Spain
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) in the Occurrence of Serious Cardiovascular Outcomes

ClinicalTrials.gov · NCT03993132 · Registry updated: 2024-02-12

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: Boehringer Ingelheim
Countries with listed sites: Denmark
Registry dates and results: Start: 2018-10-01. Completion: 2022-06-16 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Empagliflozin (drug)
Liraglutide (drug)

Where the study takes place — 1 listed sites

Department of Clinical Epidemiology - Aarhus Unversiteteshospital
Aarhus, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Effect of Liraglutide on Glucagon Secretion in Subjects With Type 2 Diabetes

ClinicalTrials.gov · NCT01509742 · Registry updated: 2024-02-01

Condition / research focus: Diabetes; Diabetes Mellitus, Type 2
Sponsor: Novo Nordisk A/S
Countries with listed sites: Germany
Registry dates and results: Start: 2001-04. Completion: 2001-11 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

liraglutide (drug) — also listed as: NNC 90-1170
placebo (drug)

Where the study takes place — 1 listed sites

Novo Nordisk Investigational Site
Bad Lauterberg im Harz, Germany
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Efficacy of Glucagon-like Peptide-1 Receptor Agonists According to Type 2 Diabetes Subtypes

ClinicalTrials.gov · NCT06120556 · Registry updated: 2024-01-30

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
Countries with listed sites: Italy
Registry dates and results: Start: 2023-06-10. Completion: 2023-10-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GLP-1 receptor agonist (drug)

Where the study takes place — 1 listed sites

Azienda Ospedaliero-Universitaria Policlinico Bari
Bari, Italy
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes

ClinicalTrials.gov · NCT02518945 · Registry updated: 2024-01-24

Condition / research focus: Type 1 Diabetes Mellitus
Sponsor: University at Buffalo
Countries with listed sites: United States
Registry dates and results: Start: 2015-08. Completion: 2016-04 (may be estimated). Results are posted in this registry.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Dapagliflozin (drug) — also listed as: Farxiga
Insulin (drug) — also listed as: Lantus, Levemir, Toujjeo, Humalog , Novolog, Apidra
Liraglutide (drug) — also listed as: Victoza
Dapagliflozin placebo (drug) — also listed as: Placebo

Where the study takes place — 1 listed sites

ECMC Ambulatory Center, 3rd Floor
Buffalo, New York, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Early Phase 1UnknownINTERVENTIONAL

The Effect of GLP-1 Agonist in Patients With Hypothalamic Obesity: Prospective, Pilot Study

ClinicalTrials.gov · NCT06217848 · Registry updated: 2024-01-23

Condition / research focus: Panhypopituitarism; Craniopharyngioma; Hypothalamic Obesity
Sponsor: Seoul National University Hospital
Countries with listed sites: South Korea
Registry dates and results: Start: 2022-11-28. Completion: 2024-03-08 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Saxenda (drug)

Where the study takes place — 1 listed sites

Seoul National University Hospital
Seoul, Jongno-gu, South Korea
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Liraglutide in Type 1 Diabetes

ClinicalTrials.gov · NCT01722240 · Registry updated: 2024-01-23

Condition / research focus: Type 1 Diabetes
Sponsor: University at Buffalo
Countries with listed sites: United States
Registry dates and results: Start: 2012-11-01. Completion: 2019-07-29 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide 1.8mg (drug)
Placebo (drug)

Where the study takes place — 1 listed sites

Diabetes-Endocrinology Center of WNY
Buffalo, New York, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Liraglutide Effectiveness in Preoperative Weight-loss for Bariatric-metabolic Surgery

ClinicalTrials.gov · NCT06201819 · Registry updated: 2024-01-18

Condition / research focus: Weight Loss; Bariatric Surgery Candidate; Obesity, Morbid
Sponsor: Hospital Civil Juan I. Menchaca
Countries with listed sites: Mexico
Registry dates and results: Start: 2022-12-18. Completion: 2023-05-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide injection (drug)

Where the study takes place — 1 listed sites

Departamento de Cirugia Bariatrica y Metabolica del Hsopital Civil Dr. Juan I. Menchaca
Guadalajara, Jalisco, Mexico
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Liraglutide in the Treatment of Type 1 Diabetes Mellitus

ClinicalTrials.gov · NCT01722266 · Registry updated: 2024-01-05

Condition / research focus: Type 1 Diabetes
Sponsor: University at Buffalo
Countries with listed sites: United States
Registry dates and results: Start: 2012-11-01. Completion: 2014-12-01 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug) — also listed as: Victoza
Placebo (drug)

Where the study takes place — 1 listed sites

Diabetes-Endocrinology Center of Western NY
Williamsville, New York, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Comparison of Two Liraglutide Formulations in Healthy Volunteers

ClinicalTrials.gov · NCT01508897 · Registry updated: 2024-01-02

Condition / research focus: Diabetes; Healthy
Sponsor: Novo Nordisk A/S
Countries with listed sites: Germany
Registry dates and results: Start: 2004-05-28. Completion: 2004-06-30 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

liraglutide (drug)
liraglutide (drug)

Where the study takes place — 1 listed sites

Novo Nordisk Investigational Site
Neu-Ulm, Germany
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Effect of Liraglutide vs CPAP on Cardiometabolic Outcomes in Obstructive Sleep Apnea

ClinicalTrials.gov · NCT04186494 · Registry updated: 2023-12-18

Condition / research focus: Sleep Apnea, Obstructive
Sponsor: St Vincent's University Hospital, Ireland
Countries with listed sites: Ireland
Registry dates and results: Start: 2019-12-02. Completion: 2022-07-31 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml (drug)
Continuous positive airway pressure treatment (device)
Liraglutide and CPAP (combination_product)

Where the study takes place — 1 listed sites

St Vincent's University Hospital
Dublin, Dublin 4, Ireland
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Effects of Degludec/Liraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic Inpatients

ClinicalTrials.gov · NCT05360537 · Registry updated: 2023-12-15

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: University of Palermo
Countries with listed sites: Italy
Registry dates and results: Start: 2021-04-01. Completion: 2022-04-20 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Insulin Degludec / Liraglutide Injectable Product (drug) — also listed as: Insulin Degludec/Liraglutide
Insulin Glargine (drug) — also listed as: glargine

Where the study takes place — 1 listed sites

Internal Medicine Ward, University of Palermo
Palermo, Italy
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableActive, not recruitingINTERVENTIONAL

Liraglutide in the Prevention of Type 2 Diabetes After Gestational Diabetes

ClinicalTrials.gov · NCT04324229 · Registry updated: 2023-12-06

Condition / research focus: Gestational Diabetes
Sponsor: Turku University Hospital
Countries with listed sites: Finland
Registry dates and results: Start: 2020-02-07. Completion: 2027-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide 6 MG/ML [Victoza] (drug)
Placebos (drug)

Where the study takes place — 1 listed sites

Turku University Hospital
Turku, Finland
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

To Predict Weight Loss Response to Liraglutide (Saxenda®), From fMRI-based Determination of Food Cue Reactivity

ClinicalTrials.gov · NCT03795701 · Registry updated: 2023-12-04

Condition / research focus: Obesity
Sponsor: Texas Tech University
Countries with listed sites: United States
Registry dates and results: Start: 2019-01-08. Completion: 2022-05-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Saxenda® (drug) — also listed as: Liraglutide 3.0
Placebo (other)

Where the study takes place — 2 listed sites

Texas Tech Neuroimaging Institute
Lubbock, Texas, United States
Site recruitment: Not reported
Nutrition & Metabolic Health Initiative
Lubbock, Texas, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS

ClinicalTrials.gov · NCT03151005 · Registry updated: 2023-12-04

Condition / research focus: Polycystic Ovary Syndrome (PCOS); Overweight; Obesity
Sponsor: Xinqiao Hospital of Chongqing
Countries with listed sites: China
Registry dates and results: Start: 2017-07-01. Completion: 2021-04-23 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Metformin-GLP-1 Receptor Agonist (drug) — also listed as: Metformin-exenatide/liraglutide Therapy
Metformin-Oral Contraceptive(OC) (drug) — also listed as: Metformin, Diane 35

Where the study takes place — 1 listed sites

The Second Affiliated Hospital, Third Military Medical University
Chongqing, Chongqing Municipality, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Safety and Tolerability of Liraglutide in Healthy Volunteers and Subjects With Type 2 Diabetes

ClinicalTrials.gov · NCT01507285 · Registry updated: 2023-11-02

Condition / research focus: Diabetes; Diabetes Mellitus, Type 2; Healthy
Sponsor: Novo Nordisk A/S
Countries with listed sites: United Kingdom
Registry dates and results: Start: 1999-08. Completion: 1999-11 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

liraglutide (drug) — also listed as: NNC 90-1170
placebo (drug)

Where the study takes place — 1 listed sites

Novo Nordisk Investigational Site
Manchester, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 Diabetes

ClinicalTrials.gov · NCT01508949 · Registry updated: 2023-11-02

Condition / research focus: Diabetes; Diabetes Mellitus, Type 2
Sponsor: Novo Nordisk A/S
Countries with listed sites: Denmark
Registry dates and results: Start: 2001-06. Completion: 2002-03 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

liraglutide (drug) — also listed as: NNC 90-1170
placebo (drug)

Where the study takes place — 1 listed sites

Novo Nordisk Investigational Site
Frederiksberg C, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira

ClinicalTrials.gov · NCT03862716 · Registry updated: 2023-10-25

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: Population Health Research Institute
Countries with listed sites: Canada
Registry dates and results: Start: 2019-04-23. Completion: 2023-07-31 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

IDegLira (drug) — also listed as: insulin degludec / liraglutide
insulin degludec (drug)
Metformin (drug)
Lifestyle Therapy (behavioral) — also listed as: diet and exercise

Where the study takes place — 8 listed sites

University of Calgary
Calgary, Alberta, Canada
Site recruitment: Not reported
University of Alberta
Edmonton, Alberta, Canada
Site recruitment: Not reported
Nova Scotia Health Authority
Halifax, Nova Scotia, Canada
Site recruitment: Not reported
McMaster University
Hamilton, Ontario, Canada
Site recruitment: Not reported
St. Joseph's Hospital
London, Ontario, Canada
Site recruitment: Not reported
Western University
London, Ontario, Canada
Site recruitment: Not reported
LMC Manna Research
Oakville, Ontario, Canada
Site recruitment: Not reported
The Ottawa Hospital
Ottawa, Ontario, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3UnknownINTERVENTIONAL

Liraglutide and Metformin Combination on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With PCOS, Obesity and Infertility

ClinicalTrials.gov · NCT05952882 · Registry updated: 2023-10-23

Condition / research focus: Polycystic Ovary Syndrome; Obesity; Infertility, Female
Sponsor: Mỹ Đức Hospital
Countries with listed sites: No country reported
Registry dates and results: Start: 2023-11-01. Completion: 2025-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide + Metformin (drug) — also listed as: LIME
Metformin (drug) — also listed as: MET

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Daily Liraglutide for Nicotine Dependence

ClinicalTrials.gov · NCT03712098 · Registry updated: 2023-09-21

Condition / research focus: Smoking Cessation; Weight, Body
Sponsor: Rebecca Ashare
Countries with listed sites: United States
Registry dates and results: Start: 2018-11-29. Completion: 2022-05-25 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug) — also listed as: Saxenda
Placebo (drug)
Smoking Cessation Counseling (behavioral)

Where the study takes place — 1 listed sites

Center for Interdisciplinary Research on Nicotine Addiction, University of Pennsylvania
Philadelphia, Pennsylvania, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Worldwide

Africa

Pan African Clinical Trial Registry ↗

Americas

Asia

Middle East

Europe

Oceania

Australia / New Zealand — ANZCTR ↗

Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.

Worldwide Study Finder

Loading registry information…

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-10-07 21:51 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase not reported / not applicableCompletedOBSERVATIONAL

SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULTICENTER STUDY. SEVERAL STUDY.

ClinicalTrials.gov · NCT05136287 · Registry updated: 2024-02-28

Condition / research focus: Weight Loss; Diabetes Mellitus, Type 2; Quality of Life; Safety Issues
Sponsor: Jose Seijas Amigo
Countries with listed sites: Spain
Registry dates and results: Start: 2022-02-01. Completion: 2024-01-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GLP-1 receptor agonist (drug)

Where the study takes place — 11 listed sites

Centro de Salud de Culleredo
Culleredo, A Coruña, Spain
Site recruitment: Not reported
Centro de Salud de Fene
Fene, A Coruña, Spain
Site recruitment: Not reported
Centro de Salud de Ribeira
Ribeira, A Coruña, Spain
Site recruitment: Not reported
Hospital Clínico Universitario de Santiago de Compostela
Santiago de Compostela, A Coruña, Spain
Site recruitment: Not reported
Centro de Salud de Ribadeo
Ribadeo, Lugo, Spain
Site recruitment: Not reported
Centro de Salud de Vilalba
Vilalba, Lugo, Spain
Site recruitment: Not reported
Centro de Salud de O Carballiño
O Carballiño, Ourense, Spain
Site recruitment: Not reported
Centro de Salud Valmiñor
Nigrán, Pontevedra, Spain
Site recruitment: Not reported
Centro de Salud de O Ventorrillo
A Coruña, Spain
Site recruitment: Not reported
Centro de Salud de San Roque
Lugo, Spain
Site recruitment: Not reported
Centro de Salud Virxe Peregrina
Pontevedra, Spain
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) in the Occurrence of Serious Cardiovascular Outcomes

ClinicalTrials.gov · NCT03993132 · Registry updated: 2024-02-12

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: Boehringer Ingelheim
Countries with listed sites: Denmark
Registry dates and results: Start: 2018-10-01. Completion: 2022-06-16 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Empagliflozin (drug)
Liraglutide (drug)

Where the study takes place — 1 listed sites

Department of Clinical Epidemiology - Aarhus Unversiteteshospital
Aarhus, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Effect of Liraglutide on Glucagon Secretion in Subjects With Type 2 Diabetes

ClinicalTrials.gov · NCT01509742 · Registry updated: 2024-02-01

Condition / research focus: Diabetes; Diabetes Mellitus, Type 2
Sponsor: Novo Nordisk A/S
Countries with listed sites: Germany
Registry dates and results: Start: 2001-04. Completion: 2001-11 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

liraglutide (drug) — also listed as: NNC 90-1170
placebo (drug)

Where the study takes place — 1 listed sites

Novo Nordisk Investigational Site
Bad Lauterberg im Harz, Germany
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Efficacy of Glucagon-like Peptide-1 Receptor Agonists According to Type 2 Diabetes Subtypes

ClinicalTrials.gov · NCT06120556 · Registry updated: 2024-01-30

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
Countries with listed sites: Italy
Registry dates and results: Start: 2023-06-10. Completion: 2023-10-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GLP-1 receptor agonist (drug)

Where the study takes place — 1 listed sites

Azienda Ospedaliero-Universitaria Policlinico Bari
Bari, Italy
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes

ClinicalTrials.gov · NCT02518945 · Registry updated: 2024-01-24

Condition / research focus: Type 1 Diabetes Mellitus
Sponsor: University at Buffalo
Countries with listed sites: United States
Registry dates and results: Start: 2015-08. Completion: 2016-04 (may be estimated). Results are posted in this registry.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Dapagliflozin (drug) — also listed as: Farxiga
Insulin (drug) — also listed as: Lantus, Levemir, Toujjeo, Humalog , Novolog, Apidra
Liraglutide (drug) — also listed as: Victoza
Dapagliflozin placebo (drug) — also listed as: Placebo

Where the study takes place — 1 listed sites

ECMC Ambulatory Center, 3rd Floor
Buffalo, New York, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Early Phase 1UnknownINTERVENTIONAL

The Effect of GLP-1 Agonist in Patients With Hypothalamic Obesity: Prospective, Pilot Study

ClinicalTrials.gov · NCT06217848 · Registry updated: 2024-01-23

Condition / research focus: Panhypopituitarism; Craniopharyngioma; Hypothalamic Obesity
Sponsor: Seoul National University Hospital
Countries with listed sites: South Korea
Registry dates and results: Start: 2022-11-28. Completion: 2024-03-08 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Saxenda (drug)

Where the study takes place — 1 listed sites

Seoul National University Hospital
Seoul, Jongno-gu, South Korea
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Liraglutide in Type 1 Diabetes

ClinicalTrials.gov · NCT01722240 · Registry updated: 2024-01-23

Condition / research focus: Type 1 Diabetes
Sponsor: University at Buffalo
Countries with listed sites: United States
Registry dates and results: Start: 2012-11-01. Completion: 2019-07-29 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide 1.8mg (drug)
Placebo (drug)

Where the study takes place — 1 listed sites

Diabetes-Endocrinology Center of WNY
Buffalo, New York, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Liraglutide Effectiveness in Preoperative Weight-loss for Bariatric-metabolic Surgery

ClinicalTrials.gov · NCT06201819 · Registry updated: 2024-01-18

Condition / research focus: Weight Loss; Bariatric Surgery Candidate; Obesity, Morbid
Sponsor: Hospital Civil Juan I. Menchaca
Countries with listed sites: Mexico
Registry dates and results: Start: 2022-12-18. Completion: 2023-05-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide injection (drug)

Where the study takes place — 1 listed sites

Departamento de Cirugia Bariatrica y Metabolica del Hsopital Civil Dr. Juan I. Menchaca
Guadalajara, Jalisco, Mexico
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Liraglutide in the Treatment of Type 1 Diabetes Mellitus

ClinicalTrials.gov · NCT01722266 · Registry updated: 2024-01-05

Condition / research focus: Type 1 Diabetes
Sponsor: University at Buffalo
Countries with listed sites: United States
Registry dates and results: Start: 2012-11-01. Completion: 2014-12-01 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug) — also listed as: Victoza
Placebo (drug)

Where the study takes place — 1 listed sites

Diabetes-Endocrinology Center of Western NY
Williamsville, New York, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Comparison of Two Liraglutide Formulations in Healthy Volunteers

ClinicalTrials.gov · NCT01508897 · Registry updated: 2024-01-02

Condition / research focus: Diabetes; Healthy
Sponsor: Novo Nordisk A/S
Countries with listed sites: Germany
Registry dates and results: Start: 2004-05-28. Completion: 2004-06-30 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

liraglutide (drug)
liraglutide (drug)

Where the study takes place — 1 listed sites

Novo Nordisk Investigational Site
Neu-Ulm, Germany
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Effect of Liraglutide vs CPAP on Cardiometabolic Outcomes in Obstructive Sleep Apnea

ClinicalTrials.gov · NCT04186494 · Registry updated: 2023-12-18

Condition / research focus: Sleep Apnea, Obstructive
Sponsor: St Vincent's University Hospital, Ireland
Countries with listed sites: Ireland
Registry dates and results: Start: 2019-12-02. Completion: 2022-07-31 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml (drug)
Continuous positive airway pressure treatment (device)
Liraglutide and CPAP (combination_product)

Where the study takes place — 1 listed sites

St Vincent's University Hospital
Dublin, Dublin 4, Ireland
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Effects of Degludec/Liraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic Inpatients

ClinicalTrials.gov · NCT05360537 · Registry updated: 2023-12-15

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: University of Palermo
Countries with listed sites: Italy
Registry dates and results: Start: 2021-04-01. Completion: 2022-04-20 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Insulin Degludec / Liraglutide Injectable Product (drug) — also listed as: Insulin Degludec/Liraglutide
Insulin Glargine (drug) — also listed as: glargine

Where the study takes place — 1 listed sites

Internal Medicine Ward, University of Palermo
Palermo, Italy
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableActive, not recruitingINTERVENTIONAL

Liraglutide in the Prevention of Type 2 Diabetes After Gestational Diabetes

ClinicalTrials.gov · NCT04324229 · Registry updated: 2023-12-06

Condition / research focus: Gestational Diabetes
Sponsor: Turku University Hospital
Countries with listed sites: Finland
Registry dates and results: Start: 2020-02-07. Completion: 2027-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide 6 MG/ML [Victoza] (drug)
Placebos (drug)

Where the study takes place — 1 listed sites

Turku University Hospital
Turku, Finland
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

To Predict Weight Loss Response to Liraglutide (Saxenda®), From fMRI-based Determination of Food Cue Reactivity

ClinicalTrials.gov · NCT03795701 · Registry updated: 2023-12-04

Condition / research focus: Obesity
Sponsor: Texas Tech University
Countries with listed sites: United States
Registry dates and results: Start: 2019-01-08. Completion: 2022-05-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Saxenda® (drug) — also listed as: Liraglutide 3.0
Placebo (other)

Where the study takes place — 2 listed sites

Texas Tech Neuroimaging Institute
Lubbock, Texas, United States
Site recruitment: Not reported
Nutrition & Metabolic Health Initiative
Lubbock, Texas, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS

ClinicalTrials.gov · NCT03151005 · Registry updated: 2023-12-04

Condition / research focus: Polycystic Ovary Syndrome (PCOS); Overweight; Obesity
Sponsor: Xinqiao Hospital of Chongqing
Countries with listed sites: China
Registry dates and results: Start: 2017-07-01. Completion: 2021-04-23 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Metformin-GLP-1 Receptor Agonist (drug) — also listed as: Metformin-exenatide/liraglutide Therapy
Metformin-Oral Contraceptive(OC) (drug) — also listed as: Metformin, Diane 35

Where the study takes place — 1 listed sites

The Second Affiliated Hospital, Third Military Medical University
Chongqing, Chongqing Municipality, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Safety and Tolerability of Liraglutide in Healthy Volunteers and Subjects With Type 2 Diabetes

ClinicalTrials.gov · NCT01507285 · Registry updated: 2023-11-02

Condition / research focus: Diabetes; Diabetes Mellitus, Type 2; Healthy
Sponsor: Novo Nordisk A/S
Countries with listed sites: United Kingdom
Registry dates and results: Start: 1999-08. Completion: 1999-11 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

liraglutide (drug) — also listed as: NNC 90-1170
placebo (drug)

Where the study takes place — 1 listed sites

Novo Nordisk Investigational Site
Manchester, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 Diabetes

ClinicalTrials.gov · NCT01508949 · Registry updated: 2023-11-02

Condition / research focus: Diabetes; Diabetes Mellitus, Type 2
Sponsor: Novo Nordisk A/S
Countries with listed sites: Denmark
Registry dates and results: Start: 2001-06. Completion: 2002-03 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

liraglutide (drug) — also listed as: NNC 90-1170
placebo (drug)

Where the study takes place — 1 listed sites

Novo Nordisk Investigational Site
Frederiksberg C, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira

ClinicalTrials.gov · NCT03862716 · Registry updated: 2023-10-25

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: Population Health Research Institute
Countries with listed sites: Canada
Registry dates and results: Start: 2019-04-23. Completion: 2023-07-31 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

IDegLira (drug) — also listed as: insulin degludec / liraglutide
insulin degludec (drug)
Metformin (drug)
Lifestyle Therapy (behavioral) — also listed as: diet and exercise

Where the study takes place — 8 listed sites

University of Calgary
Calgary, Alberta, Canada
Site recruitment: Not reported
University of Alberta
Edmonton, Alberta, Canada
Site recruitment: Not reported
Nova Scotia Health Authority
Halifax, Nova Scotia, Canada
Site recruitment: Not reported
McMaster University
Hamilton, Ontario, Canada
Site recruitment: Not reported
St. Joseph's Hospital
London, Ontario, Canada
Site recruitment: Not reported
Western University
London, Ontario, Canada
Site recruitment: Not reported
LMC Manna Research
Oakville, Ontario, Canada
Site recruitment: Not reported
The Ottawa Hospital
Ottawa, Ontario, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3UnknownINTERVENTIONAL

Liraglutide and Metformin Combination on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With PCOS, Obesity and Infertility

ClinicalTrials.gov · NCT05952882 · Registry updated: 2023-10-23

Condition / research focus: Polycystic Ovary Syndrome; Obesity; Infertility, Female
Sponsor: Mỹ Đức Hospital
Countries with listed sites: No country reported
Registry dates and results: Start: 2023-11-01. Completion: 2025-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide + Metformin (drug) — also listed as: LIME
Metformin (drug) — also listed as: MET

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Daily Liraglutide for Nicotine Dependence

ClinicalTrials.gov · NCT03712098 · Registry updated: 2023-09-21

Condition / research focus: Smoking Cessation; Weight, Body
Sponsor: Rebecca Ashare
Countries with listed sites: United States
Registry dates and results: Start: 2018-11-29. Completion: 2022-05-25 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug) — also listed as: Saxenda
Placebo (drug)
Smoking Cessation Counseling (behavioral)

Where the study takes place — 1 listed sites

Center for Interdisciplinary Research on Nicotine Addiction, University of Pennsylvania
Philadelphia, Pennsylvania, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →